Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Aug 02, 2022 Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference Jul 28, 2022 Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens Jul 27, 2022 Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Jul 14, 2022 Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update Jul 14, 2022 Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies Jul 13, 2022 Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management Jul 12, 2022 CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal Jul 07, 2022 Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update May 31, 2022 Theratechnologies Announces New Head of Investor Relations May 10, 2022 Appointments in Conjunction With Theratechnologies Annual Meeting First page « Previous page ‹ … Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Page 12 Page 13 Page 14 … Next page › Last page » Displaying 91 - 100 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Jul 28, 2022 Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens
Jul 27, 2022 Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
Jul 14, 2022 Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
Jul 14, 2022 Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
Jul 13, 2022 Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management
Jul 12, 2022 CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
Jul 07, 2022 Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update
